Key takeaways
- • Frequency: Common (mild rate increase) — 15-20% report awareness.
- • Trial reference: SUSTAIN-6 / SELECT (semaglutide CV outcomes) (15-20% awareness).
- • Management: Track resting heart rate at home — note baseline before starting, recheck after each dose increase
- • Call your prescriber if: Resting heart rate consistently >100 bpm
Why this happens
GLP-1 receptor activation has direct cardiac effects, raising resting heart rate by ~3-7 bpm on average. The mechanism is incompletely understood but appears mediated by sympathetic activation. In most patients this is asymptomatic; some perceive it as fluttering or skipped beats.
How to manage it
- Track resting heart rate at home — note baseline before starting, recheck after each dose increase
- Limit caffeine — it compounds the effect
- Avoid stimulants (decongestants, pre-workout supplements) during titration
- Stay well-hydrated — dehydration worsens palpitation perception
- Regular cardio exercise improves vagal tone and dampens awareness
- Sleep adequately — sleep debt elevates resting heart rate
GLP1Zoom doesn't prescribe — these are general management guidance from FDA labels and clinical trial reports. Personalized recommendations require your prescribing clinician.
When to call your doctor
Red flags — seek medical attention
- • Resting heart rate consistently >100 bpm
- • Palpitations + chest pain, shortness of breath, or fainting (call 911)
- • Irregularly irregular rhythm felt at the pulse (possible atrial fibrillation)
- • New or worsening palpitations after starting any new medication
Drug-specific notes
- All GLP-1s: FDA labels acknowledge ~3-7 bpm resting heart rate increase; cardiovascular outcomes net positive in LEADER/SUSTAIN trials
- Wegovy: SUSTAIN-6 + SELECT trials show net cardiovascular benefit despite rate increase
Frequently asked questions
Why does heart palpitations happen on GLP-1 medications?
GLP-1 receptor activation has direct cardiac effects, raising resting heart rate by ~3-7 bpm on average. The mechanism is incompletely understood but appears mediated by sympathetic activation. In most patients this is asymptomatic; some perceive it as fluttering or skipped beats.
When should I call a doctor about heart palpitations?
Resting heart rate consistently >100 bpm Palpitations + chest pain, shortness of breath, or fainting (call 911) Irregularly irregular rhythm felt at the pulse (possible atrial fibrillation) New or worsening palpitations after starting any new medication
How common is heart palpitations on GLP-1 medications?
Common (mild rate increase) — 15-20% report awareness
Other GLP-1 symptoms
Gastrointestinal
Nausea on GLP-1 medications
Gastrointestinal
Diarrhea on GLP-1 medications
Gastrointestinal
Constipation on GLP-1 medications
Systemic
Fatigue on GLP-1 medications
Neurological
Headache on GLP-1 medications
Skin / Hair
Hair loss on GLP-1 medications
Symptom management is general guidance based on FDA-approved prescribing information. Always discuss specifics with your prescribing clinician. In medical emergencies, call 911 or go to the nearest emergency department. Full disclaimer.
References
Endocrine Society Clinical Practice Guideline: Pharmacological Management of Obesity(2015)
STEP-1 trial: Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., NEJM)(2021)
SURMOUNT-1 trial: Tirzepatide Once Weekly for Treatment of Obesity (Jastreboff et al., NEJM)(2022)
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms and Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)
SUSTAIN-6 trial: Semaglutide and Cardiovascular Outcomes (Marso et al., NEJM)(2016)
SURPASS-2 trial: Tirzepatide vs Semaglutide in Type 2 Diabetes (Frias et al., NEJM)(2021)
LEADER trial: Liraglutide and Cardiovascular Outcomes in T2D (Marso et al., NEJM)(2016)